TY - JOUR
T1 - Impact of Growth Factors and Bone Age on BMD in Children and Adolescents With Cerebral Palsy
AU - Pedersen, Marianne Lindblad
AU - Zaabalawi, Reem
AU - Debes, Nanette Mol
AU - Hoei-Hansen, Christina Engel
AU - Johannesen, Jesper
N1 - © 2026 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
PY - 2026/1/7
Y1 - 2026/1/7
N2 - Aim: Children with cerebral palsy (CP) have reduced bone mineral density (BMD) and increased risk of fragility fracture. Despite the critical role in skeletal development, no studies have examined insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein- 3 (IGFBP-3), and their association with BMD in children with CP when adjusted for bone age. This study assesses the relationship between IGF-1 and IGFBP-3 and BMD in children with CP while accounting for bone age adjustment. Methods: Cross-sectional study, 81 children with CP GMFCS I–V, aged 2–17 years (55.6% males), underwent clinical examination, DXA scan, blood sampling and bone age assessment. Regression analysis assessed associations between IGF-1, IGFBP-3 and BMD. Results: Bone age was 0.64 years lower than chronological age (p < 0.05). Adjusted for bone age, BMD showed a positive association with IGF-1 (p < 0.05) and IGFBP-3 (p < 0.05). BMD z-score negatively associated with CP severity (p < 0.05) and CP severity was negatively associated with IGF-1 (p < 0.5) and IGFBP-3 (p < 0.05). Conclusion: Children with CP had lower bone age than chronological age. BMD was positively associated with IGF-1 and IGFBP-3 adjusted for bone age. These findings are useful in growth hormone and osteoporosis treatment, such as Zoledronate, in CP.
AB - Aim: Children with cerebral palsy (CP) have reduced bone mineral density (BMD) and increased risk of fragility fracture. Despite the critical role in skeletal development, no studies have examined insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein- 3 (IGFBP-3), and their association with BMD in children with CP when adjusted for bone age. This study assesses the relationship between IGF-1 and IGFBP-3 and BMD in children with CP while accounting for bone age adjustment. Methods: Cross-sectional study, 81 children with CP GMFCS I–V, aged 2–17 years (55.6% males), underwent clinical examination, DXA scan, blood sampling and bone age assessment. Regression analysis assessed associations between IGF-1, IGFBP-3 and BMD. Results: Bone age was 0.64 years lower than chronological age (p < 0.05). Adjusted for bone age, BMD showed a positive association with IGF-1 (p < 0.05) and IGFBP-3 (p < 0.05). BMD z-score negatively associated with CP severity (p < 0.05) and CP severity was negatively associated with IGF-1 (p < 0.5) and IGFBP-3 (p < 0.05). Conclusion: Children with CP had lower bone age than chronological age. BMD was positively associated with IGF-1 and IGFBP-3 adjusted for bone age. These findings are useful in growth hormone and osteoporosis treatment, such as Zoledronate, in CP.
KW - bone age
KW - bone mineral density
KW - cerebral palsy
KW - insulin-like growth factor-1
KW - insulin-like growth factor-binding protein 3
UR - http://www.scopus.com/inward/record.url?scp=105026995758&partnerID=8YFLogxK
U2 - 10.1111/apa.70405
DO - 10.1111/apa.70405
M3 - Journal article
C2 - 41498594
SN - 1651-2227
JO - Acta paediatrica
JF - Acta paediatrica
ER -